Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single-dose mass balance and pharmacokinetics study of [14C]-evobrutinib in healthy male participants
NL-OMON46168Phase 1Active, not recruiting
- Sponsor
- PRA Health Sciences
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of evobrutinib in multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), sponsored by PRA Health Sciences. Primary endpoints: Rates and routes of excretion of total radioactivity, Pharmacokinetics of total radioactivity in blood and plasma and 1 more. Started Oct 2018; status: active, not recruiting.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON46168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46168.